# Pathogenesis of systemic sclerosis associated interstitial lung disease

**Authors:** Svetlana I Nihtyanova, Christopher P Denton

PMC · DOI: 10.1177/2397198320903867 · Journal of Scleroderma and Related Disorders · 2020-03-05

## TL;DR

This paper reviews the causes and mechanisms behind lung fibrosis in systemic sclerosis, highlighting key factors like inflammation and immune responses.

## Contribution

The paper proposes a new model for the pathogenesis of systemic sclerosis–interstitial lung disease based on current literature.

## Key findings

- Non-specific interstitial pneumonia is the most common histological pattern in systemic sclerosis–interstitial lung disease.
- IL6, CCL2, and transforming growth factor beta are key mediators in the disease's pathogenesis.
- Epithelial injury markers like surfactant proteins and KL-6 are associated with systemic sclerosis–interstitial lung disease.

## Abstract

Systemic sclerosis is an autoimmune disease leading to vasculopathy and fibrosis
of skin and internal organs. Despite likely shared pathogenic mechanisms, the
patterns of skin and lung fibrosis differ. Pathogenesis of interstitial lung
disease, a major cause of death in systemic sclerosis, reflects the intrinsic
disease pathobiology and is associated with distinct clinical phenotypes and
laboratory characteristics. The commonest histological pattern of systemic
sclerosis–interstitial lung disease is non-specific interstitial pneumonia.
Systemic sclerosis–interstitial lung disease pathogenesis involves multiple
components, including susceptibility and triggering factors, which could be
genetic or environmental. The process is amplified likely through ongoing
inflammation and the link between inflammatory activity and fibrosis with IL6
emerging as a key mediator. The disease is driven by epithelial injury,
reflected by markers in the serum, such as surfactant proteins and KL-6. In
addition, mediators that are produced by epithelial cells and that regulate
inflammatory cell trafficking may be important, especially CCL2. Other factors,
such as CXCL4 and CCL18, point towards immune-mediated damage or injury
response. Monocytes and alternatively activated macrophages appear to be
important. Transforming growth factor beta appears central to pathogenesis and
regulates epithelial repair and fibroblast activation. Understanding
pathogenesis may help to unravel the stages of systemic sclerosis–interstitial
lung disease, risks of progression and determinants of outcome. With this
article, we set out to review the multiple factors, including genetic,
environmental, cellular and molecular, that may be involved in the pathogenesis
of systemic sclerosis–interstitial lung disease and the mechanisms leading to
sustained fibrosis. We propose a model for the pathogenesis of systemic
sclerosis–interstitial lung disease, based on the available literature.

## Linked entities

- **Proteins:** IL6 (interleukin 6), CCL2 (C-C motif chemokine ligand 2), PF4 (platelet factor 4), CCL18 (C-C motif chemokine ligand 18)
- **Diseases:** systemic sclerosis (MONDO:0005100), interstitial lung disease (MONDO:0015925), non-specific interstitial pneumonia (MONDO:0019622)

## Full-text entities

- **Genes:** Fosl2 (fos-like antigen 2) [NCBI Gene 14284] {aka Fra-2}, Tafazzin (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 66826] {aka 5031411C02Rik, 9130012G04Rik, G4.5, Taz}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, STAT4 (signal transducer and activator of transcription 4) [NCBI Gene 6775] {aka DPMC, SLEB11}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, CCL7 (C-C motif chemokine ligand 7) [NCBI Gene 6354] {aka FIC, MARC, MCP-3, MCP3, NC28, SCYA6}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, MUC5B (mucin 5B, oligomeric mucus/gel-forming) [NCBI Gene 727897] {aka MG1, MUC-5B, MUC5, MUC9}, HLA-DPB1 (major histocompatibility complex, class II, DP beta 1) [NCBI Gene 3115] {aka DPB1, HLA-DP, HLA-DP1B, HLA-DPB}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, BTG3 (BTG anti-proliferation factor 3) [NCBI Gene 10950] {aka ANA, ANA/BTG3, APRO4, TOB5, TOB55, TOFA}, PF4 (platelet factor 4) [NCBI Gene 5196] {aka CXCL4, PF-4, SCYB4}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) [NCBI Gene 3119] {aka CELIAC1, HLA-DQB, IDDM1}, CD247 (CD247 molecule) [NCBI Gene 919] {aka CD3-ZETA, CD3H, CD3Q, CD3Z, CD3ZETA, IMD25}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IRF5 (interferon regulatory factor 5) [NCBI Gene 3663] {aka SLEB10}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Yap1 (yes-associated protein 1) [NCBI Gene 22601] {aka Yap, Yap65, Yki, Yorkie}, F13A1 (coagulation factor XIII A chain) [NCBI Gene 2162] {aka F13A}, Plaur (plasminogen activator, urokinase receptor) [NCBI Gene 18793] {aka Cd87, u-PAR, uPAR}, Mrtfa (myocardin related transcription factor A) [NCBI Gene 223701] {aka AMKL, Bsac, Mal, Mkl1, Mrtf-A}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, Btg3 (BTG anti-proliferation factor 3) [NCBI Gene 12228] {aka ANA, tob5}, IRAK1 (interleukin 1 receptor associated kinase 1) [NCBI Gene 3654] {aka IRAK, pelle}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CCL18 (C-C motif chemokine ligand 18) [NCBI Gene 6362] {aka AMAC-1, AMAC1, CKb7, DC-CK1, DCCK1, MIP-4}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, CD226 (CD226 molecule) [NCBI Gene 10666] {aka DNAM-1, DNAM1, PTA1, TLiSA1}, Fli1 (Fli1 proto-oncogene, ETS transcription factor) [NCBI Gene 14247] {aka EWSR2, Fli-1, SIC-1, Sic1}, OSM (oncostatin M) [NCBI Gene 5008], MRTFA (myocardin related transcription factor A) [NCBI Gene 57591] {aka BSAC, MAL, MKL, MKL1, MRTF-A}
- **Diseases:** VEDOSS (MESH:D001523), neutrophilia (MESH:C563010), pulmonary fibrosis (MESH:D011658), coagulation (MESH:D001778), skin and (MESH:D012871), pulmonary hypertension (MESH:D006976), autoimmune rheumatic disease (MESH:D012216), death (MESH:D003643), epithelial injury (MESH:D009375), Lung injury (MESH:D055370), drop in FVC (MESH:D020427), systemic lupus erythematosus (MESH:D008180), ILD (MESH:D017563), rheumatoid arthritis (MESH:D001172), organising pneumonia (MESH:D011014), fibrosis (MESH:D005355), disorders of the lung parenchyma (MESH:D010195), Raynaud's phenomenon (MESH:D011928), diffuse cutaneous (dc)SSc (MESH:D045743), AEC injury (MESH:C535847), autoimmune disease (MESH:D001327), disease (MESH:D004194), IPF (MESH:D054990), infection (MESH:D007239), pleuroparenchymal fibroelastosis (MESH:D004695), eosinophilia (MESH:D004802), Inflammation (MESH:D007249), cough (MESH:D003371), Systemic sclerosis (MESH:D012595), vasculopathy (MESH:D000090122), ATA (MESH:D006969), tissue injury (MESH:D017695), lung (MESH:D008171), connective tissue diseases (MESH:D003240)
- **Chemicals:** oxygen (MESH:D010100), nintedanib (MESH:C530716), tocilizumab (MESH:C502936), bleomycin (MESH:D001761), bile salts (MESH:D001647)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** -945C/G, rs2004640

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8922569/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8922569/full.md

## References

119 references — full list in the complete paper: https://tomesphere.com/paper/PMC8922569/full.md

---
Source: https://tomesphere.com/paper/PMC8922569